Baseline characteristics of atopic eczema patients enrolled in seven European registries united in the TREatment of ATopic eczema (TREAT ) registry taskforce
A. H. Musters, L. A. A. Gerbens, L. van der Gang, M. A. Middelkamp‐Hup, W. Ouwerkerk, D. J. Hijnen, E. Haufe, L. Heinrich, T. Werfel, S. Weidinger, J. Schmitt, A. Svedbom, E. K. Johansson, M. Bradley, L. B. von Kobyletzki, I. Vittrup, I. F. Ruge, J. P. Thyssen, C. Vestergaard, J. M. Carrascosa, M. de Vega, I. García‐Doval, A. Chiricozzi, L. Stingeni, P. Calzavara‐Pinton, M. R. Ardern‐Jones, N. J. Reynolds, C. Flohr, P. I. Spuls, Abstract
Background
The TREAT Registry Taskforce is a collaborative effort of international registries aiming to provide real‐world data on the long‐term efficacy, cost‐effectiveness and safety of systemic treatments and phototherapy for atopic eczema (AE).
Objectives
This study seeks to present a comprehensive overview of the demographics, prior systemic treatments, clinical characteristics and disease severity and burden at baseline among patients enrolled in seven TREAT registries. Moreover, the aim is to gain insight into the differences between the registries and to explore the current prescribing practices of various therapies for patients with AE across Europe.
Methods
Data from June 2016 to 31 October 2022, were collected from seven observational cohorts: A‐STAR (UK/Ireland), AtopyReg (Italy), Biobadatop (Spain), SCRATCH (Denmark), SwedAD (Sweden), TREATgermany (Germany) and TREAT NL/BE (Netherlands/Belgium).
Results
The analysis included 5337 patients, with a mean age of 39.1 years (6.3% paediatric, 54.4% male). Of these, 84.1% had previously received systemic treatments, primarily systemic corticosteroids (58.8%) and ciclosporin (39.0%), while 30.1% had undergone phototherapy. At enrolment, dupilumab was the most prescribed treatment (75.0%), followed by ciclosporin (7.8%) and Janus Kinase inhibitors (5.9%); only 1.7% started phototherapy. Baseline assessments showed that most patients had moderate (41.9%) to severe (30.1%) AE, with an average Eczema Area and Severity Index (EASI) score of 17.6. The Patient‐Oriented Eczema Measure (POEM) score averaged 17.2, indicating severe disease impact. The Dermatology Life Quality Index (DLQI) score averaged 13.4, and the Numerical Rating Scale (NRS) for itch was 6.4.
Conclusions
This pooled analysis from the TREAT Registry Taskforce highlights the variability and similarities in data collection across national registries, providing significant insights into the baseline characteristics of the patient population. It establishes a robust foundation for future analyses of key effectiveness and safety outcomes.